[Pharmacology profile of sunitinib malate (Sutent) Capsules) and clinical findings on this drug].
Makoto
M
Tahara
Atsushi
A
Shibata
Shizuyo
S
Yamaguchi
Yoshimasa
Y
Hamada
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D002214:Capsules; D002292:Carcinoma, Renal Cell / Q000098:blood supply / Q000188:drug therapy; D002986:Clinical Trials as Topic; D046152:Gastrointestinal Stromal Tumors / Q000098:blood supply / Q000188:drug therapy*; D006801:Humans; D007211:Indoles / Q000494:pharmacology / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000098:blood supply / Q000188:drug therapy; D009389:Neovascularization, Pathologic; D011758:Pyrroles / Q000494:pharmacology / Q000627:therapeutic use; D020797:Receptor, Platelet-Derived Growth Factor beta / Q000037:antagonists & inhibitors; D000077210:Sunitinib; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000037:antagonists & inhibitors
D000970:Antineoplastic Agents; D002214:Capsules; D007211:Indoles; D011758:Pyrroles; D020797:Receptor, Platelet-Derived Growth Factor beta; D040301:Vascular Endothelial Growth Factor Receptor-2; D000077210:Sunitinib